Michael Burkes Brophy Sells 427 Shares of Natera, Inc. (NASDAQ:NTRA) Stock
Natera, Inc. (NASDAQ:NTRA – Get Rating) CFO Michael Burkes Brophy sold 427 shares of the firm’s stock in a transaction on Thursday, June 23rd. The stock was sold at an average price of $35.76, for a total value of $15,269.52. Following the completion of the sale, the chief financial officer now directly owns 81,585 shares of the company’s stock, valued at approximately $2,917,479.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Michael Burkes Brophy also recently made the following trade(s):
- On Friday, April 22nd, Michael Burkes Brophy sold 458 shares of Natera stock. The stock was sold at an average price of $36.14, for a total value of $16,552.12.
- On Monday, March 28th, Michael Burkes Brophy sold 915 shares of Natera stock. The stock was sold at an average price of $39.63, for a total value of $36,261.45.
Shares of Natera stock traded up $2.53 during trading on Friday, hitting $41.38. 1,639,467 shares of the company’s stock traded hands, compared to its average volume of 2,066,628. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.24 and a quick ratio of 4.13. Natera, Inc. has a 1 year low of $26.10 and a 1 year high of $129.09. The stock has a market capitalization of $3.99 billion, a P/E ratio of -7.04 and a beta of 1.24. The business has a 50-day simple moving average of $36.02 and a 200-day simple moving average of $54.28.
Natera (NASDAQ:NTRA – Get Rating) last released its quarterly earnings data on Thursday, May 5th. The medical research company reported ($1.45) EPS for the quarter, beating the consensus estimate of ($1.50) by $0.05. Natera had a negative return on equity of 96.99% and a negative net margin of 81.90%. The company had revenue of $194.13 million for the quarter, compared to analysts’ expectations of $176.61 million. During the same period last year, the firm posted ($0.74) earnings per share. Natera’s revenue was up 27.5% compared to the same quarter last year. On average, equities analysts predict that Natera, Inc. will post -5.78 earnings per share for the current fiscal year.
NTRA has been the subject of a number of research reports. Morgan Stanley decreased their price objective on Natera from $118.00 to $110.00 and set an “overweight” rating for the company in a report on Monday, February 28th. Cowen decreased their price objective on Natera from $110.00 to $100.00 in a report on Friday, May 6th. Robert W. Baird decreased their price objective on Natera from $100.00 to $71.00 in a report on Friday, May 6th. The Goldman Sachs Group reduced their price target on Natera from $90.00 to $80.00 and set a “buy” rating for the company in a report on Tuesday, April 19th. Finally, Stephens assumed coverage on Natera in a report on Monday, April 25th. They set an “overweight” rating and a $54.00 price target for the company. One equities research analyst has rated the stock with a sell rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $96.73.
A number of large investors have recently made changes to their positions in NTRA. Dimensional Fund Advisors LP boosted its position in Natera by 17.5% in the third quarter. Dimensional Fund Advisors LP now owns 113,641 shares of the medical research company’s stock worth $12,659,000 after purchasing an additional 16,910 shares during the last quarter. Royal Bank of Canada boosted its position in Natera by 34.4% in the third quarter. Royal Bank of Canada now owns 60,239 shares of the medical research company’s stock worth $6,713,000 after purchasing an additional 15,422 shares during the last quarter. LPL Financial LLC boosted its position in Natera by 14.3% in the third quarter. LPL Financial LLC now owns 24,916 shares of the medical research company’s stock worth $2,777,000 after purchasing an additional 3,124 shares during the last quarter. Utah Retirement Systems boosted its position in Natera by 7.5% in the third quarter. Utah Retirement Systems now owns 4,300 shares of the medical research company’s stock worth $479,000 after purchasing an additional 300 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its position in Natera by 59.8% in the third quarter. Janus Henderson Group PLC now owns 1,116,386 shares of the medical research company’s stock worth $124,410,000 after purchasing an additional 417,793 shares during the last quarter. 96.24% of the stock is currently owned by institutional investors and hedge funds.
About Natera (Get Rating)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Natera, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Natera wasn’t on the list.
While Natera currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.